Physician profile
Eva Kosta
NPI 1205961935
$4,448.24
in general payments reported to CMS, 2019-2025
27 companies · $262 in 2025
The $262 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $404 · 2021: $746 · 2022: $1,323 · 2023: $606 · 2024: $59.19 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,043.73 | 2019-2025 | |
| Novo Nordisk INC | $887.51 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $596.41 | 2019-2022 | |
| Amgen INC. | $513.94 | 2019-2023 | Repatha |
| Abbvie INC. | $214.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $185.46 | 2022-2023 | |
| Janssen Biotech, INC. | $172.94 | 2022-2023 | Tremfya, Stelara |
| Bayer Healthcare Pharmaceuticals INC. | $142.08 | 2022-2023 | |
| Lilly USA, LLC | $111.37 | 2022-2024 | Jardiance, Zepbound, Mounjaro |
| Mannkind Corporation | $91.38 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $80.07 | 2022 | |
| Xeris Pharmaceuticals, INC. | $59.26 | 2022 | |
| Lantheus Medical Imaging, INC. | $57.90 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $40.13 | 2019 | |
| Sun Pharmaceutical Industries INC. | $25.44 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $25.11 | 2024 | Zio Xt Patch, Zio Monitor |
| Glaxosmithkline, LLC. | $24.24 | 2022 | |
| Abbott Laboratories | $24.17 | 2022 | |
| Incyte Corporation | $22.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $21.85 | 2023 | Quviviq |
| Philips North America LLC | $19.59 | 2020 | |
| Currax Pharmaceuticals LLC | $17.80 | 2022 | |
| Dynavax Technologies Corporation | $17.78 | 2021 | |
| Ardelyx, INC. | $15.81 | 2023 | Ibsrela |
| Merck Sharp & Dohme LLC | $15.51 | 2019 | |
| Grt US Holding, INC. | $11.50 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Kosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.